logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Final OS analysis of abemaciclib plus tamoxifen for patients with HR+/HER2- metastatic breast cancer

Finally, a MONARCH study yields proof of significanty longer survival with abemaciclib plus tamoxifen for patients with HR+/HER2- metastatic breast cancer.